15 September - 17 September 2014

5th RSC/SCI Symposium on GPCRs in Medicinal Chemistry

Organised by:

SCI's Fine Chemicals Group and RSC's Biological & Medicinal Chemistry Sector

Actelion Pharmaceuticals Ltd, Basel, Switzerland

Registration Closed

This event is no longer available for registration.

Synopsis

The key role of G-protein coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. 
We are pleased to announce that Actelion, Switzerland will support the fifth meeting in this series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

  • New technologies for GPCR research
  • Lead generation approaches
  • Case studies in GPCR drug development
  • Allosteric modulation
  • New ligands for peptide hormone receptors
  • Structural biology and drug design
  • First disclosures of clinical candidates
  • Medicinal chemistry case studies from leading industrial scientists

Additional features

  • Evening networking reception
  • Poster sessions
  • Conference dinner
  • Trade exhibition opportunities
  • Accommodation identified for direct booking
Programme

Day 1 - Monday 15 September

08:30
Registration and refreshments
09:25
Opening remarks
09:30
Title to be confirmed
Bernadette Byrne, Imperial College London, UK
10:10
Allosteric modulation of G protein-coupled receptors: alternative ways to train slippery serpent(ine)s
David Hall, GlaxoSmithKline, UK
10:50
Refreshments and exhibition
11:20
Discovery of TGR5 (GPBAR1) agonists
David Piotrowski, Pfizer, US
12:00
Sylvain Célanire, Addex Therapeutics, Switzerland
12:40
Lunch and exhibition
13:40
CRTh2: can residence time help?
Rick Roberts, Almirall, Spain
14:20
tmGluR5 antagonists: from discovery to clinical development
Fabrizio Gasparini, Novartis, Switzerland
15:00
CB2 agonists as novel treatments for kidney diseases
Uwe Grether, F Hoffmann-La Roche Ltd, Switzerland
15:40
Refreshments and exhibition
16:10
Evolving stable GPCRs for drug screening and structural analysis
Andreas Plückthun, ETH Zurich, Switzerland
16:50
The structural basis for ligand efficacy in the b1-Adrenoceptor
Chris Tate, MRC Laboratory of Molecular Biology, UK
17:40
Close

Day 2

09:00
Molecular basis for the unique dissociation kinetics of macitentan - a novel endothelin receptor antagonist
John Gatfield, Actelion, Switzerland
09:40
Structure-based drug design with G protein-coupled receptors: the discovery of highly selective M1 agonists
Giles Brown, Heptares, UK
10:20
Refreshments, exhibition and posters
10:50
What lessons can we learn from 20 years of chemokine receptor drug discovery?
John Cumming, AstraZeneca, UK
11:30
From structure-based chemogenomic reflection to in silico prediction of GPCR-ligand interactions
Chris de Graaf, University of Amsterdam, The Netherlands
12:10
Lunch, exhibition and posters (Two workshops will run by Chemical Computing Group during this two-hour session)
14:10
Neuroscience
To be confirmed, Janssen, Belgium
14:50
Late breaker
15:20
Late breaker
15:50
Refreshments, exhibition and posters
16:20
Novel GPR40 agonists for the treatment of type-2 diabetes
Chafiq Hamdouchi, Lilly, US
17:00
The discovery of glucagon receptor antagonists for clinical development
Emma Parmee, Merck, US
17:40
Close
1900
Conference dinner

Day 3

09:00
GPCRs: application of a multivalent approach
Dan Long, Theravance, US
09:40
Identification of novel GPR81 agonist lead series for target biology evaluation
Ola Fjellström, AstraZeneca, Sweden
10:10
Refreshments
10:40
GPR81 agonists for the treatment of dyslipidaemia and atherosclerosis
Richard Davenport, Takeda, UK
11:05
Structural insights in the molecular causes of congenital stationary night blindness
Ankita Singhal, Paul Scherrer Institute, Switzerland
11:30
Crystal structures of the human adenosine A2A receptor: from agonist binding to the activation mechanism
Guillaume Lebon, CNRS, France
12:10
Close
Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Venue and Contact

Actelion Pharmaceuticals

Gewerbestrasse 16
CH-4123 Allschwil
Switzerland

 

Maggi Churchouse

Tel: +44 (0)1359 221004

Email: maggi@maggichurchouseevents.co.uk.

Fees

GB£310 . . . . . . . . .SCI / RSC Member 
GB£95. . . . . . . . . . SCI / RSC Student
GB£390. . . . . . . . . Non-Member
GB£130 . . . . . . . . .Non Member Student

Discounted rates will be offered to RSC and SCI student members and some bursaries will be available.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com

Additional Info

Organising Committee

Adrian Hall, UCB (Co-chairman)
Simon Peace, GlaxoSmithKline (Co-chairman) 
Xavier Leroy, Actelion 
Caroline Low, Consultant 
Jon Mason, Heptares 
David Miller, Takeda

Exhibition and Sponsorship

Please contact the secretariat for details of exhibitor and sponsorship opportunities.